Acrobiosystems Co

Acrobiosystems Co Acquisitions (Net)

The Acquisitions (Net) of Acrobiosystems Co (301080.SZ) as of Nov 16, 2026 is 280.11 M CNY. In the previous year, Acquisitions (Net) was 37.37 M CNY — a change of 649.56% (higher).

Acquisitions (Net)

280.11 MCNY

YoY

649.56%

Last updated:

Acquisitions (Net) of Acrobiosystems Co is 2024 280.11 M CNY. Acquisitions (Net) of Acrobiosystems Co was 2023 37.37 M CNY. It decreases by 649.56% higher compared to the previous year.

The Acrobiosystems Co Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
9.05 M CNY
Jan 1, 2019
6.23 M CNY
Jan 1, 2020
-24.41 M CNY
Jan 1, 2021
-714.00 M CNY
Jan 1, 2022
-892.14 M CNY
Jan 1, 2023
37.37 M CNY
Jan 1, 2024
280.11 M CNY
The Acrobiosystems Co Acquisitions (Net) history
YEARAcquisitions (Net)YoY
280.11 MCNY+649.56%
37.37 MCNY-104.19%
-892.14 MCNY+24.95%
-714.00 MCNY+2,824.84%
-24.41 MCNY-492.10%
6.23 MCNY-31.18%
9.05 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Acquisitions (Net) of Acrobiosystems Co is 280.11 M CNY in 2024.

Acquisitions (Net) of Acrobiosystems Co changed from 37.37 M CNY to 280.11 M CNY, representing a 649.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co